Private Management Group Inc. Trims Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Private Management Group Inc. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 49.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 211,383 shares of the biopharmaceutical company’s stock after selling 206,514 shares during the quarter. Private Management Group Inc.’s holdings in Gilead Sciences were worth $19,525,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares in the last quarter. nVerses Capital LLC acquired a new stake in Gilead Sciences during the third quarter worth approximately $25,000. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences in the 4th quarter valued at $29,000. Valued Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. Finally, Crews Bank & Trust acquired a new position in Gilead Sciences in the fourth quarter valued at $31,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 572,824 shares of company stock valued at $53,611,715. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 1.7 %

Shares of Gilead Sciences stock opened at $99.65 on Thursday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $100.51. The business has a 50-day moving average of $92.71 and a 200-day moving average of $86.32. The company has a market capitalization of $124.19 billion, a PE ratio of 1,107.22, a P/E/G ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on GILD shares. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $84.00 price objective on shares of Gilead Sciences in a research note on Monday. Bank of America reaffirmed a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Sanford C. Bernstein began coverage on Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective for the company. Finally, Barclays lifted their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.